MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$38,856K
Proceeds from exercise of
stock options
$100K
Net cash provided by
investing activities
$26,987K
Net cash provided by
financing activities
$100K
Canceled cashflow
$11,869K
Net decrease in
cash, cash...
-$14,608K
Canceled cashflow
$27,087K
Stockbased compensation
expense
$4,744K
Right-of-use assets,
operating leases
-$1,693K
Depreciation expense
$805K
Accounts payable
$641K
Collaboration receivable
-$390K
Purchases of marketable
securities
$11,825K
Purchases of property and
equipment
$44K
Net cash used in
operating activities
-$41,695K
Canceled cashflow
$8,273K
Net loss
-$39,717K
Accrued expenses and
other current...
-$5,952K
Prepaid expenses and
other current assets
$2,461K
Operating lease
liabilities
-$1,182K
Amortization/(accretion) of marketable
securities
$548K
Deferred revenue
-$88K
Other non-current
assets
$20K
Back
Back
Cash Flow
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)
source: myfinsight.com